Evaluation of published reports of foam sclerotherapy: what do we know conclusively?

被引:13
作者
Myers, K. A. [1 ]
Roberts, S. [1 ]
机构
[1] Victoria Vein Clin, Melbourne, Vic, Australia
关键词
foam sclerotherapy; varicose; veins; reticular; telangiectases; GREAT SAPHENOUS-VEIN; ULTRASOUND-GUIDED SCLEROTHERAPY; RANDOMIZED CONTROLLED-TRIAL; POLIDOCANOL FOAM; VARICOSE-VEINS; ENDOVENOUS LASER; DETERGENT SCLEROSANTS; EFFICACY; MICROEMBOLISM; STABILITY;
D O I
10.1258/phleb.2009.009048
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: The aim was to evaluate the published literature to assess what is conclusively known about optimal technique and outcome for foam sclerotherapy. Methods: A literature search was performed for randomised controlled trials, meta-analyses and observational studies using appropriate statistical techniques with survival analysis for long-term outcome. Results: Foam is more effective than liquid for ultrasound-guided sclerotherapy. Both sclerosants commonly used are equally effective for sclerotherapy for small veins. Ultrasound signals appear in the systemic circulation in most patients after foam sclerotherapy but do not appear to be associated with serious complications. Conclusion: Little else is known about the optimal preparation of foamed sclerosants and the best technique for administering foam for sclerotherapy. Long-term studies are required to determine outcome for various techniques. There is an opportunity for many controlled trials to assess results.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 50 条
  • [41] Taking a Fresh Look at Routine Screening for Intimate Partner Violence: What Can We Do About What We Know?
    Rhodes, Karin Verlaine
    MAYO CLINIC PROCEEDINGS, 2012, 87 (05) : 419 - 423
  • [42] Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know?
    Mutabingwa, Theonest K.
    Adam, Ishag
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2013, 11 (02) : 125 - 135
  • [43] Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials
    Welzel, Tatjana
    Winskill, Carolyn
    Zhang, Nancy
    Woerner, Andreas
    Pfister, Marc
    PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)
  • [44] COVID-19 vaccine boosters: What do we know so far?
    Kherabi, Yousra
    Fiolet, Thibault
    Rozencwajg, Sacha
    Salaun, Jean-Philippe
    Peiffer-Smadja, Nathan
    ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2021, 40 (06)
  • [45] Financial market fragmentation and monetary transmission in the euro area: what do we know?
    Horvath, Roman
    JOURNAL OF ECONOMIC POLICY REFORM, 2018, 21 (04) : 319 - 334
  • [46] What do we really know about the safety and efficacy of melatonin for sleep disorders?
    Kennaway, David J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (02) : 211 - 227
  • [47] Tranexamic acid and perioperative bleeding in children: what do we still need to know?
    Goobie, Susan M.
    Faraoni, David
    CURRENT OPINION IN ANESTHESIOLOGY, 2019, 32 (03) : 343 - 352
  • [48] Substance Misuse and Abuse in Older Adults: What Do We Need to Know to Help?
    Blow, Frederic C.
    Barry, Kristen L.
    GENERATIONS, 2014, 38 (03) : 53 - 67
  • [49] What do we know about dermal bioaccessibility of metals coated on antibacterial films?
    Kwon, Seon-Woo
    Park, Junyoung
    Baek, Dong-Jun
    Kim, Haeun
    Choi, Suk Soon
    Kwon, Jung-Hwan
    An, Jinsung
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2024, 274
  • [50] Recurrent Aphthous Stomatitis: Do We Know What Patients Are Using to Treat the Ulcers?
    Sawair, Faleh A.
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2010, 16 (06) : 651 - 655